23.03.2026 • Topics

Aligning Artificial Intelligence and Laboratory Execution in Drug Discovery

From In Silico Design to In Vitro Impact

Yann Gaston-Mathé, Iktos

Photo
© Iktos

Artificial intelligence is transforming molecular design, but synthesis remains the limiting step in drug discovery. To translate computational advances into real productivity gains, organizations must better align digital design with laboratory execution. AI-driven orchestration provides a practical framework to coordinate design, synthesis, and testing within existing R&D infrastructures, accelerating the transition from in silico hypotheses to in vitro validation and improving the productivity of the DMTA cycle.

The Acceleration Paradox

Artificial intelligence is reshaping how molecules are conceived. Generative models can now explore vast regions of chemical space, proposing and optimizing candidate structures with unprecedented speed.

Read more with free registration

Register now for free and get full access to all exclusive articles from chemanager-online.com. With our newsletter we regularly send you top news from the chemistry industry as well as the latest e-issue.

Sign in or register

Company

Logo:

Iktos AI

65 rue de Prony
75017 Paris
France

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read